OBJECTIVES: A paucity of data exists on actual pathology of the contemporary patients strictly categorized as having low-risk prostate cancer. We tried to identify useful preoperative predictors of Gleason score upgrading in patients who underwent radical retropubic prostatectomy (RRP) for low-risk prostate cancer diagnosed via multi-core prostate biopsy. METHODS: A total of 203 patients who underwent radical RRP for low-risk prostate cancer, as defined by D'Amico et al.'s classification (clinical stage < or = T2a, biopsy Gleason sum < or = 6, and PSA < or = 10 ng/ml), detected via multi (> or = 12)-core prostate biopsy were enrolled. We reviewed patients preoperative and pathological data. RESULTS: Among all subjects, 81 (39.9%) were upgraded to Gleason score > or = 7 after RRP, whereas no downgrading was observed. In multivariate analysis, only preoperative PSA level (P = 0.024) and number of positive cores (P = 0.027) were observed to be independent predictors of Gleason score upgrading following RRP. Also, Gleason core upgrading was observed to be significantly associated with extraprostatic extension of tumor (P < 0.001) and positive surgical margin (P = 0.002). CONCLUSIONS: A significant proportion of patients with low-risk prostate cancer as defined by D'Amico et al.'s classification diagnosed via multi-core prostate biopsy in contemporary period may have Gleason score upgrading following RRP. For patients with low-risk prostate cancer, preoperative PSA level and number of positive cores may be useful predictors of Gleason score upgrading, which was observed to significantly associated with other adverse pathologic features.
OBJECTIVES: A paucity of data exists on actual pathology of the contemporary patients strictly categorized as having low-risk prostate cancer. We tried to identify useful preoperative predictors of Gleason score upgrading in patients who underwent radical retropubic prostatectomy (RRP) for low-risk prostate cancer diagnosed via multi-core prostate biopsy. METHODS: A total of 203 patients who underwent radical RRP for low-risk prostate cancer, as defined by D'Amico et al.'s classification (clinical stage < or = T2a, biopsy Gleason sum < or = 6, and PSA < or = 10 ng/ml), detected via multi (> or = 12)-core prostate biopsy were enrolled. We reviewed patients preoperative and pathological data. RESULTS: Among all subjects, 81 (39.9%) were upgraded to Gleason score > or = 7 after RRP, whereas no downgrading was observed. In multivariate analysis, only preoperative PSA level (P = 0.024) and number of positive cores (P = 0.027) were observed to be independent predictors of Gleason score upgrading following RRP. Also, Gleason core upgrading was observed to be significantly associated with extraprostatic extension of tumor (P < 0.001) and positive surgical margin (P = 0.002). CONCLUSIONS: A significant proportion of patients with low-risk prostate cancer as defined by D'Amico et al.'s classification diagnosed via multi-core prostate biopsy in contemporary period may have Gleason score upgrading following RRP. For patients with low-risk prostate cancer, preoperative PSA level and number of positive cores may be useful predictors of Gleason score upgrading, which was observed to significantly associated with other adverse pathologic features.
Authors: Felix K-H Chun; Alberto Briganti; Markus Graefen; Francesco Montorsi; Christopher Porter; Vincenzo Scattoni; Andrea Gallina; Jochen Walz; Alexander Haese; Thomas Steuber; Andreas Erbersdobler; Thorsten Schlomm; Sascha A Ahyai; Eike Currlin; Luc Valiquette; Hans Heinzer; Patrizio Rigatti; Hartwig Huland; Pierre I Karakiewicz Journal: Eur Urol Date: 2006-09-11 Impact factor: 20.096
Authors: Ryan S Turley; Robert J Hamilton; Martha K Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Christopher L Amling; Stephen J Freedland Journal: J Urol Date: 2008-02 Impact factor: 7.450
Authors: Felix K-H Chun; Alberto Briganti; Shahrokh F Shariat; Markus Graefen; Francesco Montorsi; Andreas Erbersdobler; Thomas Steuber; Andrea Salonia; Eike Currlin; Vincenzo Scattoni; Martin G Friedrich; Thorsten Schlomm; Alexander Haese; Uwe Michl; Renzo Colombo; Hans Heinzer; Luc Valiquette; Patrizio Rigatti; Claus G Roehrborn; Hartwig Huland; Pierre I Karakiewicz Journal: BJU Int Date: 2006-08 Impact factor: 5.588
Authors: Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Martha K Terris; Joseph C Presti Journal: Urology Date: 2007-03 Impact factor: 2.649
Authors: Fei Dong; J Stephen Jones; Andrew J Stephenson; Cristina Magi-Galluzzi; Alwyn M Reuther; Eric A Klein Journal: J Urol Date: 2008-01-22 Impact factor: 7.450
Authors: Badar M Mian; David J Lehr; Courtenay K Moore; Hugh A G Fisher; Ronald P Kaufman; Jeffery S Ross; Timothy A Jennings; Tipu Nazeer Journal: Urology Date: 2006-02 Impact factor: 2.649
Authors: Scott E Eggener; Peter T Scardino; Peter R Carroll; Michael J Zelefsky; Oliver Sartor; Hedvig Hricak; Thomas M Wheeler; Samson W Fine; John Trachtenberg; Mark A Rubin; Mak Ohori; Kentaro Kuroiwa; Michel Rossignol; Lucien Abenhaim Journal: J Urol Date: 2007-10-15 Impact factor: 7.450
Authors: Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger Journal: World J Urol Date: 2010-12-30 Impact factor: 4.226
Authors: Seyed Behzad Jazayeri; Young S Kwon; Russell McBride; Michael Leapman; Shemille Collingwood; Adele Hobbs; David B Samadi Journal: Curr Urol Date: 2017-05-30
Authors: Qiang Fu; Judd W Moul; Lionel L Bañez; Leon Sun; Vladimir Mouraviev; Dongha Xie; Thomas J Polascik Journal: Med Oncol Date: 2012-06-12 Impact factor: 3.064
Authors: John G Phillips; Ayal A Aizer; Ming-Hui Chen; Danjie Zhang; Michelle S Hirsch; Jerome P Richie; Clare M Tempany; Stephen Williams; John V Hegde; Marian J Loffredo; Anthony V D'Amico Journal: Clin Genitourin Cancer Date: 2014-03-03 Impact factor: 2.872
Authors: Qiang Fu; Judd W Moul; Lionel Bañez; Leon Sun; Vladimir Mouraviev; Donghua Xie; Thomas J Polascik Journal: Med Oncol Date: 2012-12-22 Impact factor: 3.064